LATAM Regulatory Translation for Life Sciences: The Complete Reference Hub

Latin America has six major life-sciences regulators — ANVISA (Brazil), COFEPRIS (Mexico), INVIMA (Colombia), ANMAT (Argentina), ISP (Chile), and DIGEMID/ANM (Peru) — plus a long tail of smaller authorities. No two share the same language rule. ANMAT requires a traductor público matriculado register hit for every foreign-authority document. DIGEMID accepts traducción simple but invalidates any foreign document older than two years. ISP lets a company officer sign the translation. ANVISA gives Portuguese, Spanish, or English acceptance zones per document type. COFEPRIS names the perito traductor. INVIMA requires traducción oficial with consular legalization or apostille and gives pharmaceutical CPPs a one-year currency window. Between them, they generate the seven distinct QC gates — structural inventory, numeric integrity, unit consistency, negation preservation, entity mapping, adversarial back-translation, and Document Currency — that Amavita's regulatory language infrastructure runs on every dossier. This hub page is the doorway to the six regulator-specific reference guides that operationalize each one.

The Big 6 govern roughly 80% of LATAM's pharmaceutical and medical-device market volume. Every foreign sponsor entering the region touches at least three of them, and most touch all six.

The three bands. Amavita's Three Bands of LATAM Regulatory Translation framework consolidates these into three operational tiers based on translator qualification, authentication burden, and English acceptance. ANMAT + INVIMA (top of the strictness curve). ANVISA + COFEPRIS (mid-band, document-type-specific). ISP + DIGEMID (permissive on translator qualification, but with their own hard constraints — officer liability in Chile, calendar currency in Peru).

No two regimes are identical. A dossier that clears ANMAT will not automatically clear DIGEMID (calendar problem), will not automatically clear INVIMA (apostille problem), and will not automatically clear ANVISA (Portuguese label problem). A dossier optimized for DIGEMID will fail ANMAT on translator credential. This is the structural reason why LATAM regulatory translation is not "translate once, submit six times."

Every regulator page in this reference library is structured around the same two-category × three-motion matrix, so a sponsor can find the same subsection across all six guides.

Two categories:

• Drugs — pharmaceutical products, including biologicals and biosimilars.
• Medical devices — the four-class regime (in ANVISA, COFEPRIS, INVIMA, DIGEMID) or the developing framework (in Chile, where D.Ex. 25/2026 extends control to devices generally).

Three motions per category:

1. Market access — pricing, reimbursement, HTA, national list inclusion.
2. Regulatory submissions for market clearance — the primary registration or authorization pathway.
3. Clinical research trial submissions — the authorization to conduct human clinical research.

That gives six subsections per regulator — D1 through D3 for drugs, E1 through E3 for devices — plus the cross-cutting sections on language rules, sworn vs certified translation, RFI patterns, and consolidated timelines. Every reference guide in this library follows that layout, so a sponsor comparing "device clinical-trial authorization in Argentina vs Brazil" can jump straight to the E3 section in the ANMAT guide and the E3 section in the ANVISA guide.

Seven per-regulator guides:

• ANVISA Regulatory Translation Guide (Brazil) — the RDC 751/2022 device framework, RDC 837/2023 DICD clinical-investigation dossier, RDC 947/2024 trials framework, CMED pricing.
• COFEPRIS Regulatory Translation Guide (Mexico) — NOM-072, NOM-220, RIS Art. 161, CCNPMIS pricing, IETS-adjacent HTA infrastructure.
• INVIMA Regulatory Translation Guide (Colombia) — Decreto 677/1995 pharmaceutical framework, Decreto 4725/2005 device framework, CNPMDM pricing, IETS HTA.
• ANMAT Regulatory Translation Guide (Argentina) — the ICH E6(R3) transition via Disposición 7516/2025 effective 1 December 2025, Disposición 5755/1996 sworn-translation rule, Disposición 2318/2002 device framework.
• ISP Regulatory Translation Guide (Chile) — DS 3/2010 pharmaceutical framework, Ley 20.850 (Ley Ricarte Soto) high-cost access, D.Ex. 25/2026 device-registration generalization.
• DIGEMID Regulatory Translation Guide (Peru) — DS 016-2011-SA registration framework, INS/DIIS/SUDEC two-agency trial architecture, Comunicado 008-2022-DIGEMID English acceptance perimeter.
• SRS Regulatory Translation Guide (El Salvador) — the DNM → SRS succession under Legislative Decree No. 891 effective 7 August 2024, RTCA 11.03.59:18 Mutual Recognition, RTS 11.03.02:21 §6.3.4.d castellano-or-ISO-15223-1 labelling rule.

Amavita's regulatory language infrastructure operates on seven gates. The first six emerged from Amavita's six defect classes — the pattern of translation defects that trigger RFIs across all six regulators. The 7th gate — Document Currency — was added in 2026 after the DIGEMID two-year rule and the INVIMA one-year CPP rule produced defect patterns not captured by the first six.

Gate 1 — Structural inventory. Every document required by the regulator is present, and no unauthorized document is filed. The failure mode is a missing CLC, a missing CPP, a missing GMP certificate — or their inverse: filing a document not called for by the specific pathway.

Gate 2 — Numeric integrity. Every numeric value in the translation matches the source. Amavita's canonical case is the COFEPRIS infusion-pump "999 ml/hr" decimal-comma error, where the Spanish comma and the English decimal disagreed — filed as documented in RFI Anatomy.

Gate 3 — Unit consistency. SI vs Imperial, mmHg vs kPa, µg vs mg, g vs kg. Every unit is verified against the source and against the target-country pharmacopoeial convention.

Gate 4 — Negation preservation. "Do not exceed" vs "exceed only if". A single dropped negation in an IFU or ICF is a safety defect on its face, and is one of the highest-severity translation defects any regulator will flag.

Gate 5 — Entity mapping. Names — of the manufacturer, of the holder, of the technical director, of the manufacturing site, of the product family, kit, set, system — must be identical across the CPP, the CLC, the GMP certificate, the dossier body, the IFU, and the labelling. Peru's Art. 122 CLC-anchoring rule and Argentina's Disposición 5755/1996 sworn-translation register make entity-mapping drift directly detectable.

Gate 6 — Adversarial back-translation. The target-language text is translated back into the source language by an independent linguist without sight of the source. The two source-language versions are then compared. Semantic drift, ambiguity, and terminology inconsistency surface here that no forward-only QC will catch.

Gate 7 — Document Currency (new in 2026). Every foreign-issued document in the dossier — CPP, CLC, GMP certificate, ISO 13485 certificate, FDA documentation, apostille or consular legalization — sits within its own jurisdictional validity window at the moment of filing. DIGEMID's 2-year rule and INVIMA's 1-year CPP rule are the primary drivers; ANVISA revalidation statements and Chile's Art. 47 fee-payment clock also engage this gate.

Each gate is a pass/fail check with a documented output. The seven gates together are the final release-layer commitment recorded in the cryptographic audit ledger — the receipt sponsors need when a regulator asks how a specific dossier was quality-controlled.

See Blog corrections + seventh QC gate rollout for the operational architecture of Gate 7 and the two blog corrections it drove (Chile Art. 92 → 74 item 5 / 29 No. 10 / 78; Argentina Disposición 6677/2010 repealed by Disposición 7516/2025).

Amavita's Amendment Cascade analysis documents six recurring defect classes that trigger regulator RFIs. Each regulator exposes these differently:

Amavita's RFI Anatomy deconstructs six real regulator rejections. The Chile case in that post has been corrected in the current version — the operative citation is DS 3/2010 Arts. 74 item 5 / 29 No. 10 / 78, not Art. 92 (which governs sublotes). The correction was driven by Gate 5 (Entity mapping) applied to the Amavita library itself.

The last three years compressed more LATAM regulatory change than the prior decade. The four items below are the most consequential for a sponsor's LATAM translation program.

1. Argentina — ICH E6(R3) via Disposición 7516/2025. Argentina became the first LATAM regulator to formally adopt ICH E6(R3). Disposición 7516/2025 Art. 7 repealed the older Disposición 6677/2010, effective 1 December 2025 (Boletín Oficial). Every sponsor with active or planned Argentine trials must reconcile protocol, IB, and ICF templates to the E6(R3) framework. See the ANMAT guide for the full transition matrix.

2. Brazil — RDC 837/2023 DICD framework + RDC 947/2024 general trials. ANVISA restructured the medical-device clinical-investigation pathway with RDC 837/2023, formalizing the DICD (Dossiê de Investigação Clínica de Dispositivo Médico) (ANVISA announcement). RDC 947/2024 consolidates the general clinical-trial framework. E6(R3) adoption is pending. See the ANVISA guide.

3. Chile — D.Ex. 25/2026 generalizes device registration. Chile has historically operated a ten-category device-registration regime. D.Ex. 25/2026 extends control to medical devices and IVDs generally — the single largest expansion of Chile's device registration perimeter in decades. D.Ex. 5/2025 brought immunohematology reagents under registration (in force 21 February 2026), and D.Ex. 31/2026 brought IVD reagents for microbiological qualification of blood donations under registration (ISP ANDIM). See the ISP guide.

4. Peru — Comunicado 008-2022-DIGEMID formalizes English-acceptance perimeter. Comunicado 008-2022-DIGEMID permits English for CTD Modules 3, 4, and 5 (Amavita, Preclinical LATAM). It is a comunicado, not a decree — exactly the administrative instrument Art. 28 DS 016-2011-SA designates for setting the English-acceptance perimeter. DS 028-2023 and Resolución 184-2023 established the amendment/modification distinction with associated notice and decision windows (ClinRegs Peru). See the DIGEMID guide.

Mexico and Colombia have not published equivalent LATAM-first changes in the same period; their operative frameworks — NOM-072, NOM-220, RIS Art. 161 for Mexico; Decreto 677/1995, Decreto 4725/2005 for Colombia — remain the governing texts.

For sponsors sizing a multi-country LATAM program, this section is the pivot. Every row is verified against the per-regulator guide.

Translator qualification standard

Foreign document age limits

Device classification systems

Clinical-trial authorizing agency

Beyond the six regulator reference guides, the Amavita library carries deeper analytical work on the mechanics of LATAM regulatory translation. Every piece below is cross-linked from the relevant regulator guides.

Foundational framework:

• Three Bands of LATAM Regulatory Translation — the operational tiering of the six regulators by translator qualification, authentication burden, and English acceptance.
• Regulatory Language Infrastructure vs Traditional Translation — why LATAM life-sciences translation is a systems problem, not a document problem.
• Which Regulators Accept English Dossiers — document-by-document, regulator-by-regulator English-acceptance matrix.

Translation authentication:

• Sworn vs Certified Translation for Regulatory Submissions — the terminology, and where each regulator sits.
• Costly Translation Mistakes in Regulatory Submissions — apostille sequencing, notary chains, and the failure modes at each step.

Quality control mechanics:

• Translation QC for Regulatory Dossiers — the foundational QC discipline behind the seven gates.
• RFI Anatomy — Six LATAM Regulator Rejections Deconstructed — six worked case studies with statutory citations.
• Amendment Cascade — One Protocol Change × 12-Country LATAM Stack — why one protocol change generates 12+ downstream translation tasks.
• Blog corrections + seventh QC gate rollout — the operative account of Gate 7 (Document Currency) and the two blog corrections that motivated it.

Preclinical translation:

• Preclinical Translation Requirements — 9 LATAM Regulators — CTD Module 4 translation matrix.
• Preclinical Translation Requirements — Global Regulators — comparative treatment.

Clinical readability:

• INFLESZ Threshold — Spanish ICF Readability Compliance — the ≥ 55 benchmark and why it applies across all Spanish-speaking regulators.

Sponsors typically arrive at these guides in one of three scenarios.

Scenario 1 — Entering a single LATAM country. Load the relevant regulator guide (ANVISA, COFEPRIS, INVIMA, ANMAT, ISP, or DIGEMID) and work section by section. Section B tells you the language rule. Section C tells you sworn/certified/simple. Sections D1–D3 or E1–E3 tell you what documents need translation per pathway. Section F tells you the common RFI patterns. Section G is the timeline table for planning.

Scenario 2 — Planning a regional program. Read this hub first. Use Section 6 to size the translator-qualification and document-currency delta between the countries you're entering. Then open the relevant regulator guides for the specific pathways. The seven QC gates (Section 3) tell you what the release-layer commitment looks like across the whole program.

Scenario 3 — Fixing an active RFI. Load the regulator's guide (Section F on RFI patterns), read the RFI Anatomy blog for the closest case study, and check the cure window in Section G. Peru's 2-business-day trial-file correction window and Colombia's 30-day cure windows are the tightest.

When the workflow crosses two or more regulators — which it usually does — the seven QC gates are the shared discipline. The specifics change per country. The gates do not.